LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40998092PMC12522107 | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses.Ann Allergy Asthma ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41072729无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.J Clin OncolAI 判定该论文不进入自动 KM 提取:The publication explicitly describes a Phase II clinical trial, not a Phase III trial. | PMID 41082703PMC12736402 | 2026-Jan | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study.Allergol IntPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41102077无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.Genet MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41108138无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese female patients: a randomized, active reference, double-blind, double-dummy, Phase 3 trial (EAGLE-J).J Infect ChemotherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41109603无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.J Prev Alzheimers Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图;Fig. 3:非 KM 图;Fig. 4:非 KM 图。 | PMID 41109840PMC12811769 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41110692无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41110693无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41110694无 PMCID | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.J Clin Oncol | PMID 41115255PMC12736403 | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.J Allergy Clin ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41115533无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials.Am J Clin Dermatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:森林图/亚组分析图;Fig. 5:森林图/亚组分析图;另有 1 张未列出。 | PMID 41118053PMC12860764 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41120017无 PMCID | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial.VirologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41125063无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.CNS Drugs疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:非 KM 图。 | PMID 41128833PMC12769595 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| POYANG: A phase III randomized clinical trial of faricimab for choroidal neovascularization secondary to pathologic myopia: study design and rationale.Graefes Arch Clin Exp OphthalmolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41152620无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinical Performance of Tissue- and Plasma-Based Diagnostic Assays in Identifying Homologous Recombination Repair Gene Alterations in Patients with Metastatic Castration-Resistant Prostate Cancer following Treatment with Niraparib with Abiraterone Acetate Plus Prednisone (Niraparib + AAP).J Mol Diagn疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41167302无 PMCID | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.Lancet Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41173015无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.Lancet Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41173016无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41173355无 PMCID | 2026-Jan | 0.95 | The record is an original report from a randomized Phase III oncology trial, but it evaluates the quality assurance of a radiotherapy intervention (non-drug) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it fails two key eligibility criteria: drug intervention and time-to-event endpoint. | 无 KM 图 |
| Serum Vitamin A Is Associated with Variations in the Relationship between Plasma B6 Vitamers and Cardiovascular Disease Risk.J Nutr入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41176280PMC12881668 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study.BioDrugs疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:森林图/亚组分析图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。 | PMID 41182658PMC12790503 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.Obesity (Silver Spring)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE 5:生活质量量表图。 | PMID 41187013PMC12724063 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).Diabetes Obes Metab已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other。 | PMID 41187967PMC12673442 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。 | PMID 41187971PMC12673425 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图;Extended Data Fig. 1:非 KM 图;Extended Data Fig. 2:身体组成变化图。 | PMID 41188524PMC12823427 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.NEJM Evid已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图。 | PMID 41211981PMC13148048 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Population Pharmacokinetic and Exposure-Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis.Clin Pharmacokinet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:AI 判定为 other;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。 | PMID 41212510PMC12783266 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.Am J Clin Dermatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图。 | PMID 41219577PMC12860806 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.Diabetes Obes Metab疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。 | PMID 41236870PMC12673466 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the prospective, randomised, phase III Evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial.Eur J Surg Oncol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41240797无 PMCID | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Effects of intraoperative higher versus lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR): a multicentre, international, randomised, controlled, phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41240959无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.BioDrugs已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。 | PMID 41247398PMC12790509 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial.Psychiatry Clin Neurosci已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:CONSORT/入组流程图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。 | PMID 41251319PMC12757765 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.Adv Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:森林图/亚组分析图。 | PMID 41251890PMC12858542 | 2026-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pooled safety analysis of pimitespib for the treatment of patients with advanced gastrointestinal stromal tumors.Int J Clin Oncol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41264161PMC12769986 | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study.J Diabetes Investig疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:非 KM 图。 | PMID 41269878PMC12757660 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41274168无 PMCID | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.J Diabetes ComplicationsPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41289823无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies.J Clin LipidolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41298176无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Prognostic impact of lymphadenectomy in patients with advanced ovarian clear cell carcinoma: an ancillary analysis of the JGOG3017-A4 study.Int J Clin Oncol入排复审未纳入:The study is an ancillary analysis of a phase III trial evaluating a surgical intervention (lymphadenectomy), not a drug-containing intervention. Therefore, it does not meet the criteria for a drug-containing randomized trial. | PMID 41298960PMC12769647 | 2026-Jan | 0.90 | The study is an ancillary analysis of a phase III trial evaluating a surgical intervention (lymphadenectomy), not a drug-containing intervention. Therefore, it does not meet the criteria for a drug-containing randomized trial. | 无 KM 图 |
| Effect of water, sanitation, and hygiene on childhood growth in Ethiopia: a cluster-randomized trial.Int J Hyg Environ Health入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41314021无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Amustaline/glutathione pathogen-reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial.Transfusion疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图。 | PMID 41317318PMC12857873 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41319450无 PMCID | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial.Gastric Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41343125无 PMCID | 2026-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension.J Alzheimers Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:AI 判定为 other。 | PMID 41364455PMC13279984 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose.Hemodial Int已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 forest plot;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。 | PMID 41376433PMC12817161 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis.Mult Scler Relat DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41380509无 PMCID | 2026-Jan | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions.InflammopharmacologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41396379无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |